近日,港交所官网披露,凌科药业(浙江)股份有限公司递表港交所主板,中信证券、建银国际为联席保荐人。招股书信息显示,凌科药业是立足中国、面向全球的领先制药公司,专注开创治疗肿瘤、免疫及炎症疾病的新型药物。公司由资深药物开发专家创立,团队成员在药物探索领域经验丰富。其在推进产品开发管线方面效率卓越,核心产品LNK01001及LNK01004取得重大进展,首个候选产品预计将进入临床前阶段。核心产品...
Source Link近日,港交所官网披露,凌科药业(浙江)股份有限公司递表港交所主板,中信证券、建银国际为联席保荐人。招股书信息显示,凌科药业是立足中国、面向全球的领先制药公司,专注开创治疗肿瘤、免疫及炎症疾病的新型药物。公司由资深药物开发专家创立,团队成员在药物探索领域经验丰富。其在推进产品开发管线方面效率卓越,核心产品LNK01001及LNK01004取得重大进展,首个候选产品预计将进入临床前阶段。核心产品...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.